Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia

NCT00739999 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT00739999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
May 31, 2009
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric heterozygous hypercholesterolemia